Valion enters into side letter for Series B Preferred shares

Valion Bio and 3i LP amended a Series B Preferred Purchase Agreement to allow for additional closings capped at $1.55 million of Series B Preferred Shares and Warrants. The agreement is part of a financing strategy involving multiple preferred stock and note issuances.